Radiopharmaceutical CRO Market

Radiopharmaceutical CRO Market Latest Trends

The Radiopharmaceutical CRO Market is moving toward integrated development models in which sponsors rely on fewer vendors across radiochemistry, imaging, dosimetry, preclinical testing, clinical operations, and regulatory execution. This model reduces handoffs between laboratories, imaging core facilities, clinical teams, and isotope logistics providers. Integrated CRO-CDMO structures are gaining strategic importance because manufacturing schedules for radioactive products must align directly with patient visits and imaging sequences.

Radioligand therapy development is another defining trend. An analysis of registered programs identified 411 radioligand-therapy trials, confirming that development is extending beyond established PSMA and somatostatin-receptor programs toward FAP, CAIX, GRPR, and other molecular targets. CROs are consequently adding capabilities for therapeutic dosimetry, quantitative SPECT, PET imaging, biodistribution assessment, and radionuclide-specific protocol design.

Targeted alpha therapy is also changing outsourced research requirements. Actinium, astatine, and lead-based development programs require specialized radiochemistry, sensitive imaging, radiation-protection procedures, analytical methods, and isotope-access strategies. CROs able to support alpha emitters can differentiate themselves from conventional oncology trial providers.

Digital image analysis is becoming integral to clinical workflows. Central imaging laboratories increasingly combine scanner harmonization, quantitative image processing, lesion assessment, dosimetry calculation, and clinical data integration. Sponsors are also seeking standardized processes that allow imaging information to support patient selection and therapeutic response assessments. Theranostic development strengthens this trend because the same biological target may guide diagnostic imaging, treatment eligibility, administered activity decisions, and follow-up evaluation.

Radiopharmaceutical CRO Market Dynamics

Radiopharmaceutical development creates outsourcing demand because sponsors must coordinate pharmaceutical research with nuclear medicine operations. Unlike conventional clinical programs, radioactive drug studies can require synchronized manufacturing, isotope release, shipping, patient preparation, administration, imaging, sample collection, and decay-sensitive analysis. CRO selection therefore depends on technical infrastructure as well as conventional clinical-trial capacity.

The competitive environment favors providers with qualified imaging networks, radiation expertise, clinical operations teams, regulatory specialists, and established radioactive-material workflows. Expansion of targeted radionuclide therapy is increasing the strategic importance of dosimetry, centralized image review, nuclear medicine site training, and specialized logistics. At the same time, isotope availability, infrastructure requirements, fragmented national rules, specialist-workforce constraints, and site qualification can restrict execution. These conditions make radiopharmaceutical CRO outsourcing a technically differentiated service market rather than a standard extension of general pharmaceutical research.

Drivers of Market Growth

Expansion of Targeted Radioligand Therapy Development.

Targeted radioligand therapy is the primary demand driver for the Radiopharmaceutical CRO Market because development programs require multiple specialized services that sponsors may not maintain internally. Industry-sponsored oncology radiopharmaceutical trials reached 58 newly posted studies in a recent annual assessment, showing stronger commercial participation in a field that historically had significant academic involvement.

As candidates progress, CRO responsibilities expand from biodistribution and toxicity testing into clinical protocol design, nuclear medicine site identification, imaging acquisition, dosimetry, patient recruitment, pharmacokinetic evaluation, safety monitoring, and regulatory documentation. Targeted therapies also create complex multidisciplinary study teams involving oncologists, nuclear medicine physicians, medical physicists, radiochemists, imaging scientists, and clinical operations personnel.

Pharmaceutical groups entering radioligand therapy through acquisitions and licensing agreements frequently need external infrastructure immediately. Building radioactive-material laboratories, specialist imaging systems, validated analytical methods, and geographically distributed clinical networks internally can delay programs. An experienced CRO can provide an established operating framework, allowing sponsors to access specialist resources while retaining strategic control of the investigational asset.

Market Restraints

Short Radioisotope Half-Lives Restrict Clinical and Logistics Flexibility.

Radioactive decay creates a fundamental operational constraint for the Radiopharmaceutical CRO Market. Fluorine-18 has a physical half-life of 109.8 minutes, meaning production, quality release, transport, administration, imaging, and related sample workflows must be executed within tightly controlled schedules.

The logistics burden influences site selection because a hospital may require dependable access to a cyclotron, radiopharmacy, licensed distributor, or qualified local manufacturing partner. Shipment disruption can affect dosing schedules in ways that conventional pharmaceutical trials do not encounter. CROs must therefore coordinate isotope availability alongside normal patient scheduling and clinical monitoring.

Infrastructure also limits the number of suitable research facilities. A site may have experienced oncologists yet lack radioactive-drug storage, calibrated imaging equipment, radiation-safety processes, trained nuclear medicine staff, or permission to handle a specific isotope. Sponsors consequently face narrower site pools and additional qualification requirements. These restrictions can complicate multinational enrollment, protocol standardization, contingency planning, and scheduling, particularly for studies requiring repeated imaging or treatment cycles.

Market Opportunities

Greater Outsourcing of Multicountry Radiopharmaceutical Clinical Programs.

Multicountry development represents a major opportunity because complex radiopharmaceutical trials increasingly require centralized operational control. In European clinical research data, CRO-backed radiopharmaceutical studies accounted for 60.1% of planned clinical sites, demonstrating that outsourced programs can carry a substantial share of site-management responsibility.

CROs can create value by integrating country submissions, hospital contracting, nuclear medicine feasibility, investigator identification, scanner qualification, imaging manuals, radiation dosimetry, safety oversight, and clinical supply planning. This integrated model becomes increasingly relevant when sponsors want consistent quantitative imaging across geographically dispersed centers.

Emerging Asian research hubs create additional opportunity. China, Japan, and India are developing isotope-production capacity, molecular-imaging infrastructure, specialist hospitals, and domestic radiopharmaceutical pipelines. CROs capable of connecting these markets with U.S. and European regulatory programs can support globally distributed development.

Theranostic trials also expand the service opportunity because diagnostic and therapeutic workflows may need coordinated protocols, companion imaging strategies, patient-selection criteria, and dosimetry. Providers that combine clinical execution with scientific imaging expertise can therefore capture a broader portion of the development pathway.

Market Challenges

Limited Availability of Specialized Radiopharmaceutical Trial Infrastructure.

The principal challenge for the Radiopharmaceutical CRO Market is the mismatch between pipeline expansion and specialized operating capacity. A conventional oncology research site cannot automatically conduct radiopharmaceutical studies. Facilities require nuclear medicine expertise, radioactive-material authorization, calibrated imaging equipment, trained staff, radiation monitoring, suitable storage, controlled waste procedures, and access to reliable isotope supply.

Personnel constraints also influence execution. Medical physicists, dosimetrists, radiochemists, nuclear medicine physicians, imaging technologists, and clinical operations specialists must work within the same protocol framework. Competition for this workforce increases when multiple sponsors pursue similar radionuclides and molecular targets.

Another challenge is protocol consistency. Quantitative imaging can vary when scanners, reconstruction methods, acquisition parameters, calibration procedures, and image-analysis techniques differ between hospitals. CROs must establish detailed imaging charters and quality-control systems before enrollment scales.

Regulatory complexity adds another layer. Radioactive drugs intersect pharmaceutical requirements with radiation-protection rules and national transport controls. CROs that lack dedicated nuclear medicine expertise can encounter delays in site activation, supply planning, dosimetry implementation, and trial standardization.

Radiopharmaceutical CRO SWOT Analysis

Strengths

• Specialized CROs combine clinical operations with radiochemistry, nuclear imaging, dosimetry, and radiation-safety knowledge.

• Integrated service models reduce coordination gaps between preclinical laboratories, imaging teams, clinical sites, and radioactive-drug suppliers.

• Experienced providers maintain relationships with nuclear medicine investigators and hospitals that are difficult for new entrants to reproduce quickly.

• Regulatory knowledge covering pharmaceutical development and radioactive-material requirements strengthens sponsor confidence in complex global studies.

These capabilities give the Radiopharmaceutical CRO Market a defensible technical position within the wider pharmaceutical outsourcing industry. Specialized knowledge is embedded in staff training, validated workflows, imaging procedures, site networks, and scientific interpretation rather than relying only on conventional monitoring capacity.

Weaknesses

• Specialist infrastructure limits scalability compared with conventional clinical research services.

• Dependence on isotope producers creates supply-chain exposure outside direct CRO control.

• Qualified nuclear medicine sites are distributed unevenly between countries and therapeutic areas.

• Complex studies require coordination between clinical, manufacturing, imaging, physics, and regulatory functions.

The operating model can therefore become difficult to expand rapidly. Adding capacity frequently requires licensed laboratory space, specialized equipment, trained professionals, validated analytical methods, and partnerships with isotope suppliers. Smaller CROs may deliver strong scientific expertise while lacking the geographic footprint needed for large international studies.

Opportunities

• Targeted alpha therapies create demand for new imaging, dosimetry, radiochemistry, and safety capabilities.

• Theranostic programs increase outsourcing across both patient-selection imaging and treatment development.

• Pharmaceutical acquisitions of radiopharmaceutical biotechnology companies create new demand for external execution support.

• Asian and Middle Eastern nuclear medicine infrastructure provides opportunities for geographic expansion.

CROs can also develop differentiated offerings by integrating radiolabeled pharmacokinetics, quantitative image analysis, centralized imaging review, regulatory consulting, and clinical supply services. Providers able to bridge discovery, translational research, and first-in-human execution are positioned to capture programs earlier in the development cycle.

Threats

• Radioisotope shortages can disrupt trial dosing and patient schedules.

• Large pharmaceutical companies may internalize capabilities after acquiring specialist radiopharmaceutical developers.

• Regulatory divergence can make multinational execution slower and operationally fragmented.

• Competition for nuclear medicine specialists may restrict workforce availability.

Consolidation is another competitive risk because large CROs can acquire niche imaging or radiopharmaceutical expertise rather than building it organically. Smaller providers must therefore maintain scientific differentiation, rapid execution, specialized platforms, or highly focused radionuclide expertise to protect their market position.

Radiopharmaceutical CRO Segmentation Analysis

Radiopharmaceutical CRO Market segmentation reflects the technical sequence required to convert a radioactive molecular candidate into clinical evidence. Service segmentation identifies which research activities sponsors outsource, while radiopharmaceutical type separates diagnostic, therapeutic, and theranostic programs. Development-stage segmentation measures how outsourcing requirements evolve from discovery through post-approval research.

Application segmentation shows where clinical demand is concentrated, while end-user analysis identifies the organizations purchasing external development capabilities. These dimensions are interconnected. Therapeutic oncology programs may require preclinical biodistribution, radiochemistry, patient-specific imaging, dosimetry, late-stage trial execution, and specialist regulatory support within the same development plan. This structure explains why integrated CRO platforms are gaining importance.

By Service

Clinical Development & Trial Management Services hold the largest service share at 24.4%. This category includes protocol development, site management, investigator coordination, recruitment support, clinical monitoring, data management, biostatistics, and operational oversight.

Its leading position reflects the complexity of radiopharmaceutical clinical trials. Sites must align drug delivery with patient appointments, nuclear imaging, radiation controls, and protocol-defined collection schedules. Preclinical Research Services support pharmacology, biodistribution, toxicology, and PK studies, while Imaging & Dosimetry Services quantify tissue uptake and absorbed dose.

Radiochemistry Services support isotope labeling and characterization. Analytical Laboratory Services address quality, bioanalysis, and supporting assays. Regulatory Affairs specialists manage drug-development submissions and radiation-related requirements. Clinical Supply & Logistics teams coordinate time-sensitive material movement, while Other Services include project-specific scientific or operational support. Demand increasingly favors CROs that combine several of these functions within a single operating platform.

By Radiopharmaceutical Type

Therapeutic radiopharmaceuticals lead the type segmentation with a 45.2% market share. Their position reflects accelerating development of targeted radionuclide therapies for cancer and the operational complexity associated with therapeutic radiation delivery.

Therapeutic programs require dose-selection strategy, radiation dosimetry, toxicity monitoring, imaging, isotope logistics, treatment-site qualification, and coordination between oncology and nuclear medicine teams. These activities create broad CRO involvement across preclinical and clinical development.

Diagnostic radiopharmaceuticals remain important because PET and SPECT tracers support disease detection, patient selection, target verification, treatment planning, and response assessment. Diagnostic programs often depend on centralized imaging review and standardized acquisition procedures.

Theranostic programs combine diagnostic and therapeutic approaches directed at the same biological target. This model increases the importance of integrated imaging and treatment-development support because diagnostic uptake may inform patient eligibility and subsequent therapy. CROs with both imaging and clinical capabilities are therefore strategically positioned within theranostic development.

By Development Stage

Phase III represents the largest development-stage segment with a 28.2% market share. Late-stage radiopharmaceutical trials require extensive site networks, centralized operational controls, standardized imaging, statistical planning, safety monitoring, regulatory documentation, and clinical supply coordination.

Drug Discovery outsourcing focuses on target validation, tracer design, screening, and early characterization. Preclinical programs add pharmacology, biodistribution, toxicology, radiochemistry, and translational imaging.

First-in-human and Phase I studies require specialized dose escalation, pharmacokinetic analysis, biodistribution assessment, radiation dosimetry, and intensive safety oversight. Phase II programs expand patient numbers while testing efficacy, dose selection, imaging biomarkers, and treatment strategy.

Phase III execution increases operational scale and multinational coordination. Phase IV services support evidence generation after authorization, including safety monitoring and outcomes assessment. CROs that retain continuity between stages can reduce technology transfer and data-standardization problems as a program progresses from laboratory research into multicenter clinical development.

By Application

Oncology dominates application-based demand with a 67.5% market share. Cancer research benefits from molecular targets that can be visualized or treated using radionuclide-linked ligands, antibodies, peptides, and small molecules.

Oncology CRO services include tumor-target validation, preclinical imaging, biodistribution, radiation dosimetry, clinical trial management, image analysis, and regulatory support. Prostate cancer and neuroendocrine tumors have established radioligand therapy pathways, while development programs are expanding into additional solid and hematologic malignancies.

Neurology applications use molecular imaging to investigate neurodegeneration, receptor biology, disease progression, and therapeutic response. Cardiology programs employ radiopharmaceutical approaches for myocardial perfusion, functional imaging, and cardiovascular research.

Infectious-disease applications investigate targeted visualization and characterization of biological processes associated with infection. Other Applications include research areas where molecular imaging or targeted radionuclide delivery can provide mechanistic or clinical information. Application diversification gives specialized CROs opportunities beyond their established oncology client base.

By End User

Radiopharmaceutical companies represent the largest end-user category with a 42.0% market share. These developers often maintain core intellectual property and product strategy internally while outsourcing specialized laboratory, imaging, clinical, regulatory, and logistics activities.

Pharma & Biotech Companies are becoming increasingly important as major drug developers establish radioligand pipelines through internal research, acquisitions, collaborations, and licensing. Their programs can require global trial networks and integrated CRO capabilities.

Academic & Research Institutes remain central to target discovery, radiochemistry innovation, translational imaging, and investigator-led studies. Academic programs may use CRO services when research transitions into regulated clinical development or requires standardized multicenter execution.

Other end users include organizations involved in nuclear medicine research, isotope development, imaging technology, and specialized clinical programs. CROs serving multiple customer types benefit from diversified demand but must adapt operating models to different sponsor structures, development objectives, governance systems, and regulatory responsibilities.

Regional Analysis

The Radiopharmaceutical CRO Market has a geographically concentrated structure because nuclear medicine expertise, pharmaceutical research intensity, isotope-production capacity, qualified imaging centers, and regulatory infrastructure vary substantially between regions. North America maintains the leading position, while Europe has mature radiochemistry and clinical-trial capabilities. Asia-Pacific is building domestic pharmaceutical pipelines and advanced imaging infrastructure, creating strong outsourcing potential.

Middle East & Africa remains less developed but is gaining nuclear medicine capacity through investments in oncology, diagnostic imaging, precision medicine, hospitals, and life-science infrastructure. Regional expansion strategies increasingly depend on access to licensed sites, isotope logistics, specialist investigators, and regulatory expertise rather than conventional clinical-research capacity alone.

• North America

North America holds a 46.0% share of the global Radiopharmaceutical CRO Market, establishing the region as the largest geographic market. Leadership is supported by a concentrated pharmaceutical and biotechnology industry, established CRO networks, major academic medical centers, nuclear medicine expertise, and a large base of oncology clinical research.

The U.S. is the principal contributor. Sponsors operating in the country have access to PET and SPECT imaging facilities, experienced nuclear medicine physicians, radiation oncologists, medical physicists, imaging core laboratories, and pharmaceutical research centers. Regulatory experience with diagnostic and therapeutic radiopharmaceuticals also strengthens the outsourcing ecosystem.

Clinical programs increasingly require CROs to integrate medical monitoring with imaging and dosimetry. Providers that combine centralized imaging review, site qualification, clinical operations, data management, and radiation expertise can reduce fragmentation between study functions.

Canada contributes through isotope expertise, academic research, nuclear medicine centers, and pharmaceutical collaboration. Domestic capabilities in isotope science can support translational research and emerging targeted therapies.

The regional competitive advantage also comes from sponsor density. Pharmaceutical companies acquiring or licensing radiopharmaceutical pipelines often need external support rapidly, favoring CROs with existing clinical networks and validated imaging systems. North American providers are consequently expanding radiochemistry, dosimetry, radiolabeled DMPK, nuclear imaging, and radioactive-material logistics to capture a larger part of the development workflow.

• Europe

Europe accounted for 26.08% of the radiotracer preclinical CRO benchmark, indicating a substantial specialized research base within the broader radiopharmaceutical outsourcing ecosystem. The figure applies specifically to the radiotracer preclinical subset rather than the entire Radiopharmaceutical CRO Market.

Germany, the UK, France, Italy, Spain, Denmark, Sweden, and other European markets contribute established pharmaceutical research and nuclear medicine capabilities. Germany combines a major pharmaceutical industry with radiochemistry, imaging, hospitals, and specialized research institutions. The UK supports radiopharmaceutical development through life-science clusters, universities, clinical centers, and molecular-imaging expertise.

European radiopharmaceutical trials frequently involve multicountry execution. CROs therefore compete on regulatory coordination, country start-up knowledge, hospital contracting, investigator networks, imaging standardization, and radioactive-drug logistics. The need to harmonize PET and SPECT procedures across centers makes imaging core-lab capability particularly valuable.

The region also has substantial experience with theranostic medicine. Nuclear medicine institutions have used target-specific imaging and radionuclide treatment concepts across several oncology applications, creating an experienced investigator base for sponsored development programs.

European competition includes large multinational CROs and specialist radiopharmaceutical providers. Specialist firms can differentiate through dosimetry, radiochemistry, imaging science, regulatory strategy, or nuclear-medicine trial operations, while global providers compete through scale and multinational site management.

• Asia-Pacific

Asia-Pacific represented 20.41% of the radiotracer preclinical CRO benchmark, demonstrating an established regional base for specialized radioactive-tracer research. This percentage applies to the preclinical radiotracer segment rather than the entire Radiopharmaceutical CRO Market.

China is strengthening domestic radiopharmaceutical research, isotope production, pharmaceutical development, hospital infrastructure, and oncology clinical research. Large patient pools and increasing biotechnology activity create opportunities for CROs providing preclinical studies, radiochemistry, clinical trial management, imaging, dosimetry, and regulatory support.

Japan has long-standing expertise in PET, SPECT, molecular imaging, radiochemistry, and pharmaceutical development. Its mature healthcare infrastructure supports sophisticated diagnostic and therapeutic research, including theranostic programs.

India is emerging as a strategic expansion market for specialized CROs. Pharmaceutical research capabilities, clinical-trial infrastructure, nuclear medicine centers, and domestic radiopharmaceutical activity are creating opportunities for global sponsors seeking broader geographic recruitment.

Australia and South Korea contribute advanced medical research, oncology centers, and regulated clinical environments. Across Asia-Pacific, competitive advantage increasingly depends on combining local regulatory knowledge with internationally standardized imaging and trial processes. CROs able to connect Asian nuclear medicine sites with global sponsor systems can support multinational programs while giving developers access to expanding regional research capacity.

• Middle East & Africa

A radiotracer preclinical CRO benchmark assigns 7.12% to the Rest of World category that combines markets outside North America, Europe, and Asia-Pacific; a discrete Middle East & Africa percentage is not publicly separated within that benchmark.

The Middle East & Africa Radiopharmaceutical CRO Market is nevertheless developing as governments and healthcare groups invest in advanced oncology services, diagnostic imaging, precision medicine, and life-science infrastructure. Saudi Arabia and the UAE are prominent Gulf markets for healthcare expansion, while South Africa maintains established nuclear medicine capabilities and specialist institutions.

The UAE is positioning itself as a healthcare and life-sciences hub capable of supporting international partnerships and sophisticated medical technologies. Advanced hospitals and oncology facilities can provide a base for imaging-intensive clinical research.

Saudi Arabia is expanding cancer care and specialized healthcare infrastructure, creating potential demand for radiopharmaceutical imaging, trial management, dosimetry, radiochemistry, and regulatory services. CRO market development will depend on qualified investigator availability and local radioactive-material supply networks.

South Africa provides another important regional foundation through nuclear medicine expertise, PET and SPECT capabilities, oncology research, and established hospitals. Wider regional growth depends on stronger isotope access, specialized workforce development, regulatory harmonization, and research-site investment.

Competitive Landscape

Competition in the Radiopharmaceutical CRO Market combines multinational CRO scale with specialist nuclear-medicine expertise. Large providers compete through global clinical networks, regulatory infrastructure, project management, data systems, laboratory services, and established relationships with pharmaceutical sponsors. Specialist CROs compete through radiochemistry, molecular imaging, dosimetry, radioactive-material operations, theranostic expertise, and focused scientific teams.

European clinical-trial evidence indicates CRO or specialist vendor support in 23.3% of radiopharmaceutical studies evaluated, demonstrating that outsourcing remains selective but becomes increasingly relevant as protocol complexity and geographic scale increase.

IQVIA and ICON benefit from global operational reach and established oncology capabilities. Charles River Laboratories and Pharmaron have strong preclinical platforms, while Thermo Fisher Scientific and Labcorp provide broad drug-development infrastructure. Medpace differentiates through integrated clinical operations, imaging, and dosimetry. ABX-CRO emphasizes nuclear medicine, molecular imaging, clinical quality, and theranostic development.

Perceptive is strengthening alpha-therapy capabilities, while Minerva Imaging represents the growing integrated CRO-CDMO model. Competitive strategy is shifting toward partnerships with isotope companies, imaging-technology developers, dosimetry specialists, and manufacturing organizations.

The strongest differentiation increasingly comes from controlling interfaces between functions. Sponsors value providers capable of moving a candidate from translational imaging into clinical execution without rebuilding radiochemistry, dosimetry, data, regulatory, and logistics workflows at every development stage.

List of Top Radiopharmaceutical CRO Companies

• IQVIA Holdings Inc. (U.S.)

• ICON plc (Ireland)

• Charles River Laboratories (U.S.)

• Thermo Fisher Scientific (U.S.)

• Labcorp Holdings Inc. (U.S.)

• WuXi AppTec (China)

• Medpace Holdings, Inc. (U.S.)

• Perceptive (U.S.)

• Pharmaron (China)

• ABX-CRO (Germany)

• PSI CRO (Switzerland)

Leading Companies by Market Share

• IQVIA Holdings Inc. (U.S.) — IQVIA ranked as the most active provider in a recent European CTIS radiopharmaceutical CRO activity benchmark, appearing in 38.0% of CRO-backed trials. Its position is supported by global clinical operations, oncology expertise, regulatory services, laboratories, data capabilities, and specific radiopharmaceutical clinical-development experience.

• ICON plc (Ireland) — ICON is identified with IQVIA among established global participants in current Radiopharmaceutical CRO competitive benchmarking. Its competitive position is supported by multinational clinical operations, oncology trial capabilities, imaging-related expertise, data management, regulatory support, and established pharmaceutical sponsor relationships.

Investment Trends & Opportunities

Investment in the Radiopharmaceutical CRO Market is moving toward integrated infrastructure rather than conventional clinical-trial capacity alone. Investors are targeting businesses that connect preclinical research, radiochemistry, molecular imaging, dosimetry, clinical execution, CMC support, and radioactive-drug manufacturing.

Private capital participation illustrates this strategy. In June 2025, Nordic Capital partnered with Minerva Imaging to support international expansion and strengthen its integrated radiopharmaceutical CRO-CDMO platform. The transaction highlights investor interest in service businesses positioned across several stages of radioligand development rather than a single outsourced function.

Pharmaceutical-sector consolidation also generates indirect CRO opportunities. Large drug companies have acquired specialized radiopharmaceutical developers to establish internal pipelines rapidly. Acquired portfolios still require external imaging laboratories, clinical operations, dosimetry specialists, isotope suppliers, regulatory experts, and qualified research sites.

Investment opportunities are particularly strong in alpha-emitter development, patient-specific dosimetry, radiochemistry automation, quantitative imaging, centralized image analysis, and isotope logistics. Geographic investment can also address shortages in qualified sites and regional isotope access.

CROs with existing infrastructure may use partnerships instead of constructing every capability internally. Alliances with radionuclide producers, specialized software developers, imaging laboratories, and CDMOs can expand service coverage while maintaining scientific specialization. This partnership-based model is likely to remain important as the technology mix becomes increasingly diverse.

Product Innovation & Development

Product innovation within the Radiopharmaceutical CRO Market is centered on alpha-emitting radionuclides, improved theranostic targeting, quantitative imaging, personalized dosimetry, and integrated development workflows. Actinium-225 is attracting substantial development interest because its 9.92-day physical half-life is compatible with targeted alpha-therapy research while its decay chain delivers high-energy radiation at the cellular level.

CROs are developing imaging and analytical methods capable of characterizing emerging alpha therapies. Specialized SPECT systems, quantitative imaging protocols, tissue-distribution studies, and radiation-dose models allow developers to evaluate parent radionuclides and associated decay products.

Theranostic innovation is also changing study design. Researchers can use a diagnostic agent to establish target expression and then use a related therapeutic construct to deliver radiation to selected patients. This creates demand for CRO workflows linking biomarker imaging, eligibility criteria, administered activity, lesion uptake, and outcome measurements.

Innovation is extending into conjugation chemistry. New platforms aim to connect antibodies and other targeting structures with radioactive payloads while preserving biological binding characteristics. CROs with translational models can test these constructs before clinical entry.

Digital dosimetry represents another development area. Software-supported image quantification can help study teams estimate absorbed dose in healthy organs and tumor lesions, supporting protocol design and evidence generation for increasingly personalized treatment approaches.

Recent Developments (2023–2026)

• In September 2026, Minerva Imaging appointed David A. Kroon to lead its U.S. expansion and support development of a future American radiopharmaceutical manufacturing and development presence.

• In July 2026, TD2 Oncology and Minerva Imaging formed a partnership linking oncology clinical and regulatory expertise with radiopharmaceutical imaging and manufacturing support for translation into first-in-human studies.

• In May 2026, Minerva Imaging and Debiopharm established a collaboration to integrate a precision conjugation technology into preclinical development of next-generation radiopharmaceutical and theranostic candidates.

• In January 2026, Perceptive and Atley Solutions initiated a strategic collaboration to establish commercial CRO capabilities for astatine-based targeted alpha-therapy development in the United States and United Kingdom.

• In December 2025, ABX-CRO acquired ClinSmart to strengthen clinical-quality expertise and expand integrated nuclear-medicine and theranostic trial execution across international markets.

• In June 2025, Medpace and Voximetry formalized a strategic partnership combining radiopharmaceutical clinical-trial operations with specialized dosimetry technology and services.

Scope of the Radiopharmaceutical CRO Market Report

The Radiopharmaceutical CRO Market Report covers the outsourced research, development, imaging, clinical, analytical, regulatory, and logistics services required to advance diagnostic, therapeutic, and theranostic radiopharmaceuticals. The scope evaluates how sponsors use external providers to access specialized nuclear medicine capabilities, licensed infrastructure, scientific expertise, clinical networks, and standardized development systems.

Service coverage includes Clinical Development & Trial Management Services, Preclinical Research Services, Imaging & Dosimetry Services, Radiochemistry Services, Analytical Laboratory Services, Regulatory Affairs, Clinical Supply & Logistics, and supporting specialized activities. The report also examines demand by radiopharmaceutical type and development stage.

Application analysis covers oncology, neurology, cardiology, infectious diseases, and other areas where radioactive imaging or targeted radionuclide treatment supports drug development. End-user coverage includes pharmaceutical and biotechnology companies, dedicated radiopharmaceutical developers, academic research institutions, and other organizations participating in nuclear medicine research.

Geographic analysis evaluates North America, Europe, Asia-Pacific, and Middle East & Africa with attention to clinical infrastructure, isotope availability, pharmaceutical activity, regulatory capability, nuclear medicine expertise, and CRO presence.

Competitive coverage assesses multinational CROs and specialist providers according to clinical reach, radiochemistry capability, imaging expertise, dosimetry services, preclinical resources, regulatory support, logistics capability, partnerships, acquisitions, and expansion activity. The report also evaluates investment priorities, emerging alpha-emitter platforms, theranostic development, integrated CRO-CDMO models, quantitative imaging, and technologies influencing future outsourcing decisions.